Abstract:As of December 6, 2021, coronavirus disease 2019 (COVID-19) has infected about 2.65 billion people and caused 5.26 million deaths worldwide. Vaccination is an effective approach to help control coronavirus disease 2019 (COVID-19).However, since the vaccines produce a heterogenous immune response, the risk of breakthrough infection is increased in vaccinated individuals who generate low levels of neutralizing antibodies (NAbs). It is therefore paramount in the fight against COVID-19 to identify individuals who have a higher risk of breakthrough infection despite being vaccinated. In this study, we addressed the effect of cigarette smoking on the production of NAbs following COVID-19 vaccination.We recruited 164 participants received two vaccine doses of an inactivated whole-virion SARS-CoV-2 vaccine (Sinovac-CoronaVac) two weeks apart (i.e., Day0 and Day14), which were divided into smoking and nonsmoking groups. The longitudinal changes (0, 14, 42, 90 days) of anti-Spike (S) antibodies and NAbs in serum were detected using a protein array and SARS-CoV-2 pseudovirus neutralization assay with the D614G substitution, respectively.Antibody levels to S protein and domains (S1, S2ECD, RBD) were elevated 14 and 42 days after COVID-19 vaccination compared to baseline in both participant groups (i.e., Day0).Moreover, RBD antibodies showed significantly higher expression in the nonsmoking group (n=153) than the smoking (n=11) group on day 42 (p<0.0001, Student's t-test).The NAbs continually increased after the first and second vaccine dose, peaking on day 42. NAbs titers then significantly decreased until day 90. Compared to nonsmokers, the NAb levels in smokers remained low throughout the period of testing. Notably, the median NAb titers in the smoking group was 1.40-, 1.32-, or 3.00-fold lower than that of nonsmoking group on day 14, 42, or 90, respectively. No correlation was observed between NAbs and other factors [(i.e., age, sex, body-mass index (BMI)]. Altogether, our results indicate that smoking is a specific risk factor for COVID-19 breakthrough infection following vaccination. Further investigation of smoking and how it affects NAb levels in response to COVID-19 vaccination with a larger patient cohort and other COVID-19 vaccines is warranted.

Relationship between Anti–SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination

Early Elevated Inflammatory Markers in SARS-CoV-2 Vaccinated Patients Are Associated with Reduced Mortality, Morbidity, and Lung Injury

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients

Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

SARS-CoV-2-reactive IFN-γ-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia

Hospital Outcomes in Patients Hospitalized for COVID-19 Pneumonia: The Effect of SARS-CoV-2 Vaccination and Vitamin D Status

The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome

High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19

Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19

The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study

Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study

Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

Analysis of related factors of plasma antibody levels in patients with severe and critical COVID-19

IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes

Clinical and laboratory features in health care volunteers with inactivated SARS-CoV-2 vaccination

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Anti-SARS-CoV-2 Antibodies versus Vaccination Status in CAD Patients with COVID-19: A Prospective, Propensity Score-Matched Cohort Study

Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers